Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours
M Goswami, NJ Toney, SC Pitts… - Clinical and …, 2024 - Wiley Online Library
Background With the rapid adoption of immunotherapy for the treatment of cancer comes the
pressing need for readily accessible biomarkers to guide immunotherapeutic strategies and …
pressing need for readily accessible biomarkers to guide immunotherapeutic strategies and …
Evolving immunotherapeutic solutions for triple-negative breast carcinoma
S Wu, A Ge, X Deng, L Liu, Y Wang - Cancer Treatment Reviews, 2024 - Elsevier
Triple-negative breast carcinoma (TNBC) remains a formidable clinical hurdle owing to its
high aggressiveness and scant therapeutic options. Nonetheless, the evolving landscape of …
high aggressiveness and scant therapeutic options. Nonetheless, the evolving landscape of …
Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast …
O White, S Dent, K Westbrook, HJ Lee, C Yang… - Breast Cancer Research …, 2024 - Springer
Purpose This study aimed to assess safety and efficacy of a modified KEYNOTE 522
protocol, which incorporated pembrolizumab every 6 weeks, allowing for concomitant dose …
protocol, which incorporated pembrolizumab every 6 weeks, allowing for concomitant dose …
[HTML][HTML] 48 Serum analytes associate with clinical outcomes in patients with triple negative breast cancer enrolled in the OXEL trial treated with nivolumab …
NJ Toney, MT Lynch, F Lynce, C Mainor, C Isaacs… - 2024 - jitc.bmj.com
Background The OXEL study (NCT03487666) is an open label phase II trial for patients with
triple negative breast cancer (TNBC) and residual disease after neoadjuvant chemotherapy …
triple negative breast cancer (TNBC) and residual disease after neoadjuvant chemotherapy …
Utilizing Nano-Crystals to Enhance the Efficiency of Capeticabin on Cadherins in Breast Cancer Treatment
S Bazilbayev, R Atraubaeva, A Alipbayev… - Journal of …, 2024 - jns.kashanu.ac.ir
Breast most cancers stays a huge fitness project, necessitating progressive approaches to
enhance remedy efficacy. Cadherins, essential for cell adhesion and signalling, play a …
enhance remedy efficacy. Cadherins, essential for cell adhesion and signalling, play a …
The Role of UBR2 in Triple-Negative Breast Cancer and Its Implications for Immune Checkpoint Blockade Therapy
Y Jiang, Y Fu, X Song, Y Xie, X Shang, X Liang - 2025 - researchsquare.com
Objective UBR2 (also referred to as n-recognin 2, the E3 component of ubiquitin protein
ligase) targets proteins with unstable N-terminal residues for polyubiquitination and …
ligase) targets proteins with unstable N-terminal residues for polyubiquitination and …
1223 Machine learning models for predicting clinical outcomes in patients with triple negative breast cancer treated with immunotherapy, chemotherapy, or …
MT Lynch, NJ Toney, F Lynce, C Mainor, C Isaacs… - 2024 - jitc.bmj.com
Background The OXEL study (NCT03487666) is a phase II trial that enrolled patients with
triple-negative breast cancer (TNBC) and residual disease following neoadjuvant …
triple-negative breast cancer (TNBC) and residual disease following neoadjuvant …